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Summary The etiology of essential hypertension includes increased oxidative stress. The role
of antihypertensive drug amlodipine as an antioxidant and the benefit of addition of vitamin
C, an antioxidant to antihypertensive therapy were studied. Forty male patients of essential
hypertension were randomly divided into two groups and treated with 5 mg amlodipine. In
addition one group also received 1000 mg vitamin C (as two 500 mg tablets) once daily for
three months. Although blood pressure decreased in both groups, the systolic blood pressure
in patients given vitamin C was less (126.4 ± 7.47) compared to the other group (130.9 ± 7.27).
A decrease in malondialdehyde, an increase in erythrocyte sodium-potassium adenosine
triphosphatase (Na+ K + ATPase) and an increase in the superoxide dismutase levels were
observed in both groups. The increase in SOD was statistically more in the patients given
vitamin C in addition to amlodipine (0.1717 ± 0.0150 compared to 0.152 ± 0.0219 units/100 ml
assay). In spite of the known antihypertensive, antioxidant activity, similarity in correcting
endothelial dysfunction independently, giving the two drugs together and early introduction of
vitamin C perhaps decreases oxidative stress and augments the antioxidant status. This may
prevent further vascular damage due to oxidative stress, leading to a better prognosis in
essential hypertension patients.
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Introduction
The pathophysiology of essential hypertension may involve
one or more abnormalities in cardiovascular homeostatic
mechanisms including endothelial dysfunction [1]. The
endothelial dysfunction is related to a defect in vasodilator
nitric oxide (NO) synthesis. There may be an elevation of
reactive oxygen species (ROS) like superoxide anion, which
inactivate the NO. Normally compounds like tocopherol
and ascorbic acid, the endogenous antioxidant mechanism
involving enzymes like catalase, superoxide dismutase (SOD)
and glutathione scavenge and regulate the superoxide
formed. This protective mechanism may be defective in
essential hypertension patients. [2–4]. Free radicals and
organic peroxides also decrease erythrocyte Na+ K+ ATPase
levels by affecting the pump activity and antioxidants may
prevent this inhibition. The changes in erythrocyte membrane
reflect similar changes occurring in the vascular smooth
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muscle leading to increase in vascular tone via a mechanism
involving calcium transport [5, 6]. Hence the balance between
ROS and the antioxidant may play a role in hypertension [7,
8]. This imbalance along with the ATPase activity reverts
back to normal after the control of hypertension with drugs
[9, 10]. In a recent review, antioxidant therapy has been
suggested to reduce oxidative stress in human hypertension
and end stage renal disease [11].
Antihypertensive and antianginal drugs may also exert anti-
oxidant and cytoprotective effect against free radical mediated
vascular injury [12]. Amlodipine is a long acting calcium
antagonist with vascular selectivity. Its dihydropyridine ring
reduces. The free radicals to nonreactive forms [13].
Amlodipine decreases plasma levels of vasoconstrictor,
thromboxane A, elevates vasodilators like prostacyclin, NO,
increases aortic tissue cyclic guanosine monophosphate
(cGMP) and cyclic adenosine monophosphate (cAMP) [14].
It increases NO production in pulmonary circulation in
patients of essential hypertension, probably through a
mechanism involving bradykinin [15]. It is known to up
regulate the activity of SOD [16]. Animal studies with
cholesterol fed rabbits showed that amlodipine reduced
aortic cholesterol accumulation, blood and aortic lipid
peroxidation, malondialdehyde (MDA) levels, increased
SOD in blood and aortic tissue, suppressed catalase and
consumption of vitamin E [17].
Vitamin C or ascorbic acid is an antioxidant that may also
decrease the blood pressure (BP) and influence the endothelial
dysfunction. The mechanism probably involves scavenging of
intracellular superoxide, activation of either smooth muscle
guanylyl cyclase or endothelial NO synthetase, release of
NO from tissue S- nitrosothiols and Snitrosoalbumin which
reaches the smooth muscle in vascular wall, direct reduction
of nitrite to NO, a decrease in low density lipoprotein
(LDL) oxidation [18]. However the exact dose response
relationship, effect on both systolic and diastolic BP and
mechanism of link between BP control and antioxidant
activity is still controversial [19, 20].
A study to assess the benefit of using both amlodipine and
vitamin C was done in hypertension patients. Change in
forearm blood flow after acetylcholine infusion, measured
by venous occlusion plethysmography was used to study
the endothelial function. Vitamin C (24 mg/min) for 10
minutes acutely and amlodipine (5–10 mg/day) for 2 months
chronically improved the endothelial function while a NO
synthase inhibitor blunted the improvement. Intraarterial
infusion of vitamin C, in amlodipine treated hypertensive
patients did not further increase forearm vasodilatation in
response to acetylcholine. It was suggested that since both
increase the bioavailability of NO, perhaps there is no
advantage of giving them together [21].
Thus our study was undertaken with the aim to evaluate,
the blood pressure and the oxidative, antioxidant status using
levels of malondialdehyde, erythrocyte Na+ K + ATPase
and superoxide dismutase levels respectively, in patients of
essential hypertension. We also wanted to see whether 5 mg of
amlodipine alone or when given with 1000 mg ascorbic acid
could influence these variables. Since both drugs are known
to have antihypertensive and antioxidative properties as well,
we wanted to assess the additional benefit of giving them
together for correction and prevention of further endothelial
damage.
Material and Methods
Enrolment
The study was conducted in forty male patients of essential
hypertension in the age group, 30–50 years. They were
recently diagnosed after a series of recordings with a systolic
blood pressure (SBP) between140–180 mmHg and a
diastolic blood pressure (DBP) between 90–110 mmHg.
This range was chosen to increase the availability of
patients. During screening they were advised to improve
their lifestyle by increasing physical activity (walking 3–4
times a week for 40 minutes) and restrict salt (avoid the
use of extra topping of salt). Baseline investigations of blood
sugar, urea, haemoglobin, serum electrolytes, creatinine, uric
acid, urine examination for albumin, sugar, microscopy and
specific gravity, blood urea nitrogen, electrocardiogram
(ECG), X-ray abdomen and ultrasonography of kidneys was
done.
Exclusion criteria
Patients with history, lab finding suggestive of secondary
hypertension, hyperlipidemia or any chronic disease were
excluded. Similarly those who had habits of smoking,
alcohol, substance abuse, receiving any alternate traditional
forms of therapy like ayurvedic and homeopathic medicines,
using diet supplements containing vitamins (especially
vitamin C) and requiring more than 5 mg amlodipine for
blood pressure control were excluded. The patients were
advised to restrict the use aspirin and nonsteroidal anti-
inflammatory drugs.
No strict dietary or lifestyle modifications other than pre-
viously mentioned were used in order to ensure compliance.
However one patients started yogic exercises and two
underwent dietary restrictions. They were not discouraged
but their data is not included.
Experimental protocol
Each patient served as his own control. They were
randomly divided into groups and were either given
amlodipine 5 mg alone (Aml) or amlodipine 5 mg with
1000 mg (500 mg tablet, two tablets once daily with meals)
of vitamin C (Aml + Vit C) with the goal to normalize the
BP. The dose of amlodipine was initiated in order to findBenefits of Amlodipine and Vitamin C in Hypertension
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the lowest effective dose for successful early treatment
and long-term compliance. This dose of vitamin C was
selected because previous literature has reported that
high physiological/pharmacological doses of ascorbate are
required for antioxidant reactions in hypertension and long
term moderate doses of 500 mg a day have not proved useful
as antihypertensive treatment in many studies [22–24].
Baseline height, weight and BP (after adequate rest) were
taken. A consent form was filled. Blood was collected for
estimation of biochemical parameters. Thereafter, weekly
evaluation of BP between 10.00am to 12 noon was done.
After three months of therapy, weight, BP and bio-
chemical investigations were repeated for comparison.
Weekly dispensing of medicines, counting the medicines con-
sumed, questioning about daily consumption of medicines,
associated lapses and reinforcement ensured compliance.
Biochemical investigation
Blood was collected in the morning hours; venous blood
from the anticubital vein was drawn into a clean dry dis-
posable sterile syringe under all aseptic precautions. The
blood was immediately transferred into two clean and dry
test tubes, one with and the other without the anticoagulant.
The tube with anticoagulant was centrifuged at 1500 g for 5
minutes to separate the red blood cells (RBC) from the
plasma. The plasma transferred to a clean and dry test tube.
The serum in test tube with coagulated blood was transferred
after centrifugation into another dry test-tube. Care was
taken to prevent haemolysis.
Measurement of erythrocyte Na+ K+ ATPase [25]
The methodology involved preparation of RBC ghosts,
estimation of proteins in the ghosts, ATP assay and estimation
of inorganic phosphate.
After the plasma was decanted and the buffy coat was
carefully removed, the packed RBCs were washed with 0.9%
NaCl. RBC ghosts were prepared using Tris HCl 10 mM and
EDTA 1 mM solution. They were then centrifuged at
15000 g for 5 minutes at 4°C in a refrigerated centrifuge.
The procedure was repeated thrice and the supernatant
decanted to collect the packed ghosts.
The proteins in the RBC ghosts were estimated by
reacting them with alkaline copper tartarate and then with
Folins reagent. ATP assay was done with magnesium
chloride, potassium and sodium chloride, Tris HCl and
disodium ATP. 20 mM. ATPase activity is the difference
in the amount of inorganic phosphate (Pi) liberated by
0.5 ml membrane with and without K+(KCl). Ultimately the
Na+ K+ ATPase activity was estimated as µ moles of Pi/mg
membrane protein/h.
Measurement of serum malondialdehyde [26]
Thiobarbituric acid (TBA) reacts similarly with lipid per-
oxide and MDA to give a florescent compound. Tetra-
methoxy propane converts quantitatively to MDA during the
reaction, is reacted with TBA. Relative florescence intensity
of the product was measured by flurometry at 515 nm
excitation and 553 emissions. This was compared with the
standards and the lipid peroxide levels were expressed in
terms of the MDA.
Measurement of serum superoxide dismutase [27]
Freshly prepared 2.6 mM pyrogallol in 10 mM HCl,
30 mM EDTA, tris buffer and sample were mixed. A lag of
1.5 minutes allowed for a steady state of pyrogallol to be
reached. The rate of increase in absorbance at 420 nM was
measured spectrophotometrically. This increase is prevented
by SOD as it inhibits auto oxidation of pyrogallol. One unit
of SOD activity is defined as the amount of enzyme required
to cause 50% inhibition of auto oxidation of pyrogallol per
3 ml of assay containing 0.1 ml of serum. The results are
expressed as units/100 ml of assay mixture.
Statistical analysis
The mean and standard deviation of the data was calculated.
The comparison between the baseline and the follow-up of
the two groups was compared by the paired t test. The com-
parison between the baselines, follow-up of one group with
the other was done with the unpaired t test. Similarly body
weight, body mass index, SOD levels, MDA, erythrocyte
Na+ K + ATPase was compared with the students t test. A
p<0.05 was considered significant. Pearson’s one and two
tailed test was used for correlation between BP (systolic,
diastolic) and MDA level.
Results
There was no difference in the baseline weight, body mass
index, systolic and diastolic BP between the two groups as
seen in Table 1. No significant change in weight and body
mass index was observed at the end of three months of
therapy p = 1.00, 0.94 respectively in group (Aml), p = 1.00,
1.00 respectively in group (Aml + Vit C). Table 1 shows
significant decrease in the systolic and the diastolic BP in the
two groups at the end of three months. Also a significant
difference in the two, follow-up systolic but not the diastolic
BP was now observed as measured by the unpaired one
tailed t test. (p = 0.0285).
The biochemical values are indicated in the Table 2. The
serum malondialdehyde decreased, superoxide dismutase and
Na+ K + ATPase activity increased significantly after three
months. The superoxide dismutase level was higher in the
(Aml + Vit C) group after treatment (p = 0.029). The corre-
lations between MDA level and BP were not significant.A.S. Mahajan et al.
J. Clin. Biochem. Nutr.
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Discussion
The blood pressure of our hypertensive patients decreased
when amlodipine 5 mg was given alone and along with
1000 mg vitamin C. Thus this therapy using a single anti-
hypertensive drug with lifestyle changes proved beneficial
in both stage 1 and 2 hypertensive patients [28]. Various
mechanisms of amlodipine’s action may contribute to the
decrease in BP [14, 29].
Although we cannot comment about the antihypertensive
action of vitamin C independently, the post-treatment systolic
BP was less when vitamin C was also given along with
amlodipine. Most of the studies related to vitamin C and
hypertension deal with therapeutic effect, serum levels,
dietary levels, and vasodilatory response to drugs to assess
endothelial function. Although many studies are favourable
but there is no consensus of opinion about the therapeutic
dose, duration of effect and treatment. Some studies suggest
that vitamin C decreases systolic BP, in doses 2000 mg bolus
followed by 500 mg once daily or 500 mg twice daily for a
period of 4–6 weeks in hypertensive patients [20, 30]. In
another study intravenous administration of ascorbic acid
rapidly reduced BP in hypertensive patients. A decrease of
both systolic as well as diastolic BP in a group of borderline
hypertensives has been reported [31–33]. The relationship
between dietary, serum levels of vitamin C and BP was
studied in healthy men who were given a diet deficient in
vitamin C for a month. Those with a greater decrease in
vitamin C levels had a higher BP [34]. Intrarterial adminis-
tration of vitamin C is reported to improve vasodilatory
response directly but not following amlodipine therapy in
hypertensive patients [21]. Also combinations of high oral
dose of antioxidants, zinc sulphate, vitamin C, alpha toco-
pherol and beta-carotene, when compared with placebo
treatment have shown a decrease in systolic BP in patients
receiving antihypertensive treatment [35]. The mechanism by
Table 1. Demographic profile of hypertensive patients in the beginning of the study
Parameter Aml (n = 20) Aml + Vit C (n = 20) p value
Age (years) 38.05 ± 7.51 36.57 ± 7.94 0.54
Sex Male Male
Food habits Vegetarian Vegetarian
Occupation office desk work office desk work
Height (cm) 170.30 ± 6.81 169.90 ± 5.58 0.84
Weight (kg) 75.8 ± 12.1 76.48 ± 8.86 0.18
BMI (kg/m2) 26.02 ± 3.09 26.56 ± 3.53 0.60
Baseline Systolic BP (mmHg) 158.2 ± 8.48 160.0 ± 8.67 0.25
Baseline Diastolic BP (mmHg) 97.10 ± 3.97 95.14 ± 3.77 0.06
Follow-up Systolic BP (mmHg) 130.9 ± 7.27a 126.4 ± 7.47ab 0.02
Follow-up Diastolic BP (mmHg) 82.7 ± 5.28a 81.24 ± 4.54a 0.17
Values are Mean ± standard deviation. p value denotes the difference between the two groups of
hypertension patients. p<0.05 is significant.
a Indicates significant difference between baseline and follow-up using paired t test.
b Indicates significant difference between follow-up of the two groups using one tailed unpaired t
test. df = 38.
Table 2. Changes in the biochemical profile (Baseline and follow up) in the hypertensive patients with three months
of treatment
Variable Group Baseline Follow up
Malondialdehyde nmol/ml Aml 2.07 ± 0.22 1.07 ± 0.18a
Malondialdehyde nmol/ml Aml + Vit C 1.95 ± 0.36 1.13 ± 0.35a
Superoxide dismutase Units/100 ml assay Aml 0.0704 ± 0.0155 0.1582 ± 0.0219ab
Superoxide dismutase Units/100 ml assay Aml + Vit C 0.0706 ± 0.0127 0.1717 ± 0.0150ab
RBC Na+ K+ ATPase µmolPi/mgprt RBCmemb/h Aml 0.15680 ± 0.0025 0.16905 ± 0.00590a
RBC Na+ K+ ATPase µmolPi/mgprt RBCmemb/h Aml + Vit C 0.15648 ± 0.00262 0.16886 ± 0.00360a
Values are Mean ± standard deviation. n = 20 for each group.
a Significant difference between baseline and follow up (after 3 months treatment) (p<0.001).
b Significant difference between follow up of both groups (p = 0.029; t test df = 38).Benefits of Amlodipine and Vitamin C in Hypertension
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which antioxidant vitamin C improves endothelial function
in essential hypertension is probably by directly scavenging
free radicals within the vasculature. This restores the nitric
oxide level improving endothelium dependant vasodilatation
[36]. Increase in NO synthase, increase delivery of NO
from plasma, reduction of nitrite to NO and stimulation of
guanylate cyclase by NO may be additional mechanisms
involved. [18,  37,  38]. However other authors feel that
vitamin C has very little or negligible effect on BP [19, 23].
Thus there are inconsistent reports by different authors, but
our results have shown a lower value (4 mmHg decrease) of
systolic BP, suggesting a beneficial effect of adding vitamin C
to therapy with amlodipine. However this change is significant
only by the one tailed and not the two-tailed unpaired t test.
There is need for extensive trials of longer duration if the
relevance of this BP lowering effect of vitamin C is to be
seen in the clinical or public health perspective. Till such a
time, ethical reasons may not permit its long-term use as a
single drug regime in hypertension.
The MDA levels decreased significantly in both the
groups. This decrease in MDA could be either a result of
BP reduction or antioxidant property of amlodipine. These
results are in agreement with various other studies that
have shown MDA levels to decrease after amlodipine
administration [17, 39]. Amlodipine directly reduces several
free radical species [40, 41]. Other studies however have
suggested no effect on circulating indices of oxidative stress
[42]. In experiments with spontaneously hypertensive rats
and normotensive rats, with or without amlodipine treat-
ment, no significant difference in total antioxidant capacity
was observed [43]. Vitamin C is a well-known antioxidant
that scavenges extra free radicals and whose levels inversely
correlate with those of lipid peroxides [30, 44]. In a recent
study, six months of treatment with 600 mg per day of
ascorbic acid has reported a similar decrease [45]. However
since the decrease in MDA levels in our patients was not
different in the two groups, we presume that the addition of
vitamin C was not particularly helpful in this respect.
A low level of SOD is reported in hypertensive patients.
This decrease may be associated with a decrease in NO
levels, reinforcing that SOD is helpful in the release of NO
[46, 47]. Amlodipine has been reported to increase SOD,
prevent the decrease in glutathione, and the consumption of
vitamin E, but has no effect on the catalase activity [12, 17].
SOD levels may increase due to up regulation and decreased
consumption. Increase in SOD activity, with more NO bio-
availability may be one of the mechanisms contributing to
the antioxidant properties of antihypertensives ramipril and
losartan [48]. Similarly SOD levels were lower in hyper-
tensive patients compared to controls but increased after 24
weeks of acebutolol therapy [49]. SOD levels increased in
both groups of our hypertensive patients following treatment,
more where vitamin C was given. However had we normalized
the SOD values to serum proteins, it could have helped in
better quantification of the increase, but we can definitely
state that vitamin C in therapy augments the increase in SOD
levels.
The Na+ K + ATPase activity is inhibited by oxidative
stress and hydroperoxides. It is susceptible to free radical
induced lipid peroxidation. A lower level compared to control
is reported in diabetic hypertensives. Hence the increase in the
activity is a sign of reduction in the oxidative stress [50]. An
increase is reported more with angiotensin converting enzyme
(ACE) inhibitors compared to calcium channel blockers and
also in treatment with enapril and captopril [10, 51, 52]. The
increased level in our patients following amlodipine therapy
supports the finding of MDA decrease, indicating a reduction
in oxidative stress on the RBC membrane. As the values
of both groups were not statistically different vitamin C
probably had no effect on this enzyme.
Conclusion
This study has thus shown that amlodipine therapy
decreased blood pressure, and improved the status of oxi-
dative stress as shown by a decrease in MDA and increase in
Na+ K + ATPase and SOD levels in essential hypertension
patients. It therefore has antioxidative action in addition to
the antihypertensive action. Following treatment with amlo-
dipine and 1000 mg of vitamin C, in addition to the above-
mentioned benefits another group of hypertensive patients
had a lower systolic BP and higher SOD level.
Estimation of plasma ascorbic acid, NO production, a
complete dietary analysis to study contribution of key
nutrients like sodium and potassium in the diet and a longer
follow up may be required to further ensure and state
the mechanism of benefit of that extra 1000 mg of vitamin
C in the pathophysiology of essential hypertension. How-
ever it can be definitely stated that adding vitamin C to
amlodipine therapy can further increase SOD, an enzyme
of the endogenous antioxidant mechanism which may help
to reduce and prevent further endothelial damage due to
oxidative stress in essential hypertension.
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